Abbisko Therapeutics discovers and develops small‑molecule precision‑oncology and immuno‑oncology drugs that target validated oncogenic drivers and immune pathways, such as CSF‑1R, FGFR4, KRAS G12D, EGFR C797S, PD‑L1 and CXCR4. Leveraging an in‑house multi‑dimensional R&D platform that integrates cancer genomics, medicinal chemistry and biomarker science, the company advances a pipeline of over ten oral candidates, with several in clinical stages, through monotherapy and combination trials for solid tumors and rare diseases in China and globally.

AgiBot develops and manufactures humanoid robots and embodied intelligence systems designed for various applications, including interactive services and flexible manufacturing. Their technology enhances productivity by automating tasks in diverse environments, addressing labor shortages and operational inefficiencies.

CharacterX provides a decentralized AI companion network that enables users to create, mint, and trade AI characters as NFTs, facilitating personalized interactions and content generation. The platform addresses the lack of ownership and governance in AI character creation by transforming these digital assets into tradable items on a Web3 infrastructure.

The startup develops targeted therapies for cancer treatment through drug discovery focused on tumor immunology. By enhancing the immune response against tumors, the company aims to improve the quality of life for cancer patients.

This startup offers an online platform that empowers women and LGBTQ artists to launch and manage NFT initiatives, utilizing decentralized finance tools to enhance visibility and access to resources. By fostering a community-driven ecosystem, the platform addresses the lack of equitable opportunities in the crypto space for underrepresented creators.

Insufficient publicly available information is available to determine Xido's core product, service, or value proposition.

MAYCUR.COM offers cloud-based financial products that utilize advanced data analytics and machine learning to enhance financial decision-making for businesses. The platform addresses inefficiencies in financial management by providing real-time insights and automated reporting, enabling companies to optimize their financial operations.

XinpleTek develops high-performance RF front-end solutions for mobile communication and IoT devices, utilizing advanced RF component technology to enhance wireless connectivity. Their products address the need for efficient and reliable signal transmission in the rapidly growing 5G and IoT markets.

The startup develops TCR gene therapy solutions that provide personalized immunotherapy for cancer patients by engineering T-cell receptors to target specific tumor antigens. This approach enhances treatment efficacy and minimizes side effects compared to traditional therapies.